IRVING, Texas, Nov. 7, 2017 — Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that the Company has filed a patent infringement suit against Foundation Medicine, Inc. in the United States District Court for the District of Massachusetts Boston Division. Caris is seeking damages and other relief for Foundation's willful infringement of Caris' patent rights by its FoundationOne®, FoundationACT® and FoundationOne® Heme products.
According to the complaint, Foundation Medicine infringes five U.S. Patents (Nos. 8,880,350; 9,372,193; 9,383,365; 9,092,392; and 9,292,660) held by Caris. The patents cover Caris' novel system of performing molecular profiling of tumors to identify treatment options based on groups of molecular targets not traditionally or conventionally associated with various types of cancer. The system generates a molecular profiling report, which the treating physician may then use to develop a personalized treatment plan for the patient.
“Before Caris' tumor profiling invention, cancer treatment was based on a defined list of therapy options conventionally associated with a tumor's tissue of origin,” said Russ Farr, J.D., Senior Vice President and General Counsel for Caris Life Sciences. “We have invested heavily in the development of our innovative technology for precision medicine because we strongly believe, and have demonstrated, that the molecular findings identified with tumor profiling can be utilized to provide cancer patients viable therapeutic options. We intend to vigorously defend our intellectual property and investment and take action against those who violate it.”
Caris Life Sciences is represented by Fish & Richardson in this case. To view a copy of the complaint, click here.
About Caris Life Sciences®
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation, and the world's leading immunotherapy diagnostic expert. Caris Molecular Intelligence®, the company's Comprehensive Genomic Profiling Plus (CGP+) molecular testing service, assesses DNA, RNA and proteins, including microsatellite instability (MSI), total mutational load (TML) and PD-L1, to reveal a molecular blueprint to guide more precise and personalized treatment decisions. The ADAPT Biotargeting System™, the company's revolutionary and unbiased profiling platform, is currently being utilized for drug target identification, therapeutic discovery and development, fixed tissue-based companion diagnostics, blood-based cancer screening and biomarker identification. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe and other international markets. To learn more, please visit www.CarisLifeSciences.com.
Caris Life Sciences Media Relations
SOURCE Caris Life Sciences
Latest posts by Maria Burns (see all)
- RipassoÂ Energy signs a Memorandum of Understanding to form a project financing company with capacity to acquire 72 PWR BLOK units - February 19, 2018
- AstraZeneca's IMFINZI approved for Stage III nsclc - February 19, 2018
- NOTICE OF ANNUAL GENERAL MEETING - February 19, 2018